Next Article in Journal
Development of a NIR Method for the In-Line Quantification of the Total Polyphenolic Content: A Study Applied on Ajuga genevensis L. Dry Extract Obtained in a Fluid Bed Process
Previous Article in Journal
Preparation and Improved Physical Characteristics of Propylene Oxide Rubber Composites
Open AccessArticle

Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress

1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey
2
Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey
*
Author to whom correspondence should be addressed.
Molecules 2018, 23(9), 2151; https://doi.org/10.3390/molecules23092151
Received: 26 July 2018 / Revised: 20 August 2018 / Accepted: 22 August 2018 / Published: 27 August 2018
(This article belongs to the Section Medicinal Chemistry)
Parkinson’s disease (PD) is a chronic, progressive, and age-related neurodegenerative disorder characterized by the loss of midbrain dopaminergic neurons caused by the accumulation of free radicals and oxidative stress. Based on the neuroprotective properties of 2-pyrazoline derivatives, in the current work, 1-(phenyl/4-substituted phenyl)-3-(2-furanyl/thienyl)-5-aryl-2-pyrazolines (3ai, 4ai) were synthesized via the cyclization of the chalcones (1, 2) with suitable phenylhydrazine hydrochloride derivatives. All these compounds were investigated for their neuroprotective effects using an in vitro 6-hydroxydopamine (6-OHDA)-induced neurotoxicity model of PD in the rat pheochromocytoma (PC-12) Adh cell line. In addition, some different pharmacokinetic parameters of all compounds were in silico predicted by the QikProp module of Schrödinger’s Maestro molecular modeling package. 4-Methylsulfonylphenyl substituted compounds 3h (20%) and 4h (23%) were determined as the most promising neuroprotective agents related to their inductive roles in cell viability when compared with the 6-OHDA-positive control group (43% and 42%, respectively). Moreover, in silico pharmacokinetic results indicated that all compounds were within the acceptable range intended for human use. According to both in vitro and in silico studies, compounds 3h and 4h draw attention as potential orally bioavailable therapeutic drug candidates against neurodegeneration in PD. View Full-Text
Keywords: Parkinson’s disease; neurodegeneration; 2-pyrazoline; chalcone; 6-hydroxydopamine; pharmacokinetic parameters Parkinson’s disease; neurodegeneration; 2-pyrazoline; chalcone; 6-hydroxydopamine; pharmacokinetic parameters
Show Figures

Figure 1

MDPI and ACS Style

Özdemir, A.; Sever, B.; Altıntop, M.D.; Kaya Tilki, E.; Dikmen, M. Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress. Molecules 2018, 23, 2151. https://doi.org/10.3390/molecules23092151

AMA Style

Özdemir A, Sever B, Altıntop MD, Kaya Tilki E, Dikmen M. Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress. Molecules. 2018; 23(9):2151. https://doi.org/10.3390/molecules23092151

Chicago/Turabian Style

Özdemir, Ahmet; Sever, Belgin; Altıntop, Mehlika D.; Kaya Tilki, Elif; Dikmen, Miriş. 2018. "Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress" Molecules 23, no. 9: 2151. https://doi.org/10.3390/molecules23092151

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop